Pharmacy Benefit Management

From Specialty Pharmacy News - Since the first of the immunotherapies came onto the U.S. market in 2011, these drugs have had a tremendous impact on the treatment of various cancers. However, these innovative therapies, which use an individual’s own immune system to attack cancer cells, come at a steep price to a health care system already struggling to rein in care costs. The treatments also come with certain side effects affiliated with their mechanism of action. And while almost all the current therapies have multiple approved indications, researchers are looking at their use in combination with each other, as well as with chemotherapies. A… Read more

From Drug Benefit News - CareFirst BlueCross BlueShield has become the latest health care/pharmaceutical stakeholder to draw congressional scrutiny. But it’s unclear at this point whether that attention is, in fact, warranted. On April 17, Sen. Chuck Grassley (R-Iowa) sent a letter to the insurer’s president and CEO, Chet Burrell, questioning the company’s use of so-called “brand penalties.” Imposed on members when they fill prescriptions for a brand drug when a generic is available, the penalty… Read more

Pharmacy Benefit Management Blog

By Angela Maas - May 18, 2017
On Thursday, Vertex Pharmaceuticals Inc. said it was adding Maxor National Pharmacy Services, LLC to its specialty pharmacy network on Aug. 1. Maxor is certainly not a newcomer to the industry and brings a wealth of experience and knowledge, so the move is no surprise. But what might be a surprise...
By Lauren Flynn Kelly - April 14, 2016
In the latest squabble between drugstores and PBMs, the National Community Pharmacists Association (NCPA) on April 1 issued a letter to CMS Deputy Director Cynthia Tudor asserting that Medicare Part D plans and PBMs are not complying with a federal requirement to use drug pricing standards that “...
By Angela Maas - March 30, 2016
As high drug prices continue to make headlines and draw congressional ire, hepatitis C drugs and “Mr. Wu-Tang” Martin Shkreli seem to be getting a reprieve as focus turns to the prostate cancer drug Xtandi. On March 28, 12 members of Congress sent a letter to HHS Sec. Sylvia Burwell and Francis...

It's quick and easy to sign up for FREE access to!

Why do I need to register?